Cannovex
Agoralaan Building Abis /
3590 Diepenbeek
BE
Cannovex
Foundation date
06/08/2016
Sector
#Biotechnology - otherSubsector
Therapeutic areas
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the eye
- #Diseases of the nervous system
- #Endocrine - nutritional and metabolic diseases
- #Mental and behavioural disorders
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
- #Skin and subcutaneous tissue
Cannovex is a Benelux-origin biotech company which develops cannabinoid-based medicines to improve the lives of patients worldwide. Over a two year period, Cannovex has conducted an in-depth and exhaustive study of medical literature on this subject, and continues to monitor all scientific publications. These efforts establish Cannovex as the designated conversation partner, sounding board and source of information on cannabinoid medicines for all stakeholders.
Based on the insights resulting from the above-mentioned research, Cannovex is now planning the development of cannabinoid-based medicines in specific therapeutic areas and for well-defined indications. Cannovex aims to set up clinical studies, in collaboration with EU university hospitals, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, to apply for market authorisation with European Medicines Agency (EMA) and similar authorities, and to bring our cannabinoid medicinal products to the markets worldwide.
Upcoming events
All events-
1804 '24
Anglonordic Life Science Conference 2024
Event by: BioPartner -
1605 '24
Knowledge for Growth 2024
Event by: flanders.bio -
2304 '24
BioTrinity 2024
Event by: OBN
Latest news
More news-
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Wednesday March 27th 2024
Read more
-
InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline
Tuesday March 26th 2024
Read more
-
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
Monday March 25th 2024
Read more
Jobs
More jobs-
28/03/24
Flemish Brabant
Post-doc position – Structural Bioinformatics of protein interactions
Permanent
VIB -
-
More info?
Ellen Telleir
Communication Coordinator